Skip to content
5 min read watchdog-wednesday FDA

Watchdog Wednesday: Botanical Drug Sponsors Want A Well-Trimmed Pathway

Can an emboldened RFK Jr. provide more flexibility on real-world data and manufacturing standards to botanical developers? Maybe, but more intractable exclusivity issues could be a bigger barrier for the field.

plants and beakers
New products might grow out of FDA’s reconsideration of its botanical guidance. Image by Anna Tretyak/Shutterstock.

The US FDA has been formally encouraging botanical drug submissions for more than a quarter century, and it has just four approvals to show for it. By the standards of bonsai, that is practically a growth spurt, but as regulatory pathways go, this one might be dying on the vine.

Even those that have reached the market haven’t exactly established strong commercial roots. The first of the four, the green tea extract Veregen cleared in 2006, has since been sponsored or marketed by six different companies, a career arc more befitting a journeyman relief pitcher than a pioneering drug.

So it’s fair to wonder what the agency hopes to learn from its latest request for information on botanical drug development. The docket closed on Nov. 3, which was also Election Day, and the results of the midterms reshuffled the political deck behind the effort in ways that should interest any small sponsor with a plant extract in its pipeline.